Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Viale

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Translational Cancer Research|February 4, 2022
Toward precision medicine in inflammatory breast cancerGiulia Viale, Antonio Marra, Giuseppe Curigliano, et al.
NPJ Breast Cancer|October 22, 2020
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesAntonio Marra, Dario Trapani, Giulia Viale, et al.
Expert Opinion on Investigational Drugs|March 7, 2014
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapyCarmen Criscitiello, Lucia Gelao, Giulia Viale, et al.
Expert Review of Anticancer Therapy|August 27, 2019
What therapies are on the horizon for HER2 positive breast cancer?Giulia Viale, Stefania Morganti, Emanuela Ferraro, et al.
The Oncologist|August 14, 2020
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical TrialsCarmen Criscitiello, Antonio Marra, Stefania Morganti, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2018
Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysisCarmen Criscitiello, Mehra Golshan, William T Barry, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Opportunities and challenges of implementing Pharmacogenomics in cancer drug developmentPaolo Tarantino, Dario Trapani, Stefania Morganti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2019
The evolving landscape of 'next-generation' immune checkpoint inhibitors: A reviewLuca Mazzarella, Bruno Achutti Duso, Dario Trapani, et al.
Critical Reviews in Oncology/Hematology|January 22, 2019
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real lifeStefania Morganti, Paolo Tarantino, Emanuela Ferraro, et al.
Cancer Treatment Reviews|March 5, 2018
Targeting the microenvironment in solid tumorsCarmen Belli, Dario Trapani, Giulia Viale, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Translational Cancer Research|February 4, 2022
Toward precision medicine in inflammatory breast cancerGiulia Viale, Antonio Marra, Giuseppe Curigliano, et al.
NPJ Breast Cancer|October 22, 2020
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesAntonio Marra, Dario Trapani, Giulia Viale, et al.
Expert Opinion on Investigational Drugs|March 7, 2014
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapyCarmen Criscitiello, Lucia Gelao, Giulia Viale, et al.
Expert Review of Anticancer Therapy|August 27, 2019
What therapies are on the horizon for HER2 positive breast cancer?Giulia Viale, Stefania Morganti, Emanuela Ferraro, et al.
The Oncologist|August 14, 2020
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical TrialsCarmen Criscitiello, Antonio Marra, Stefania Morganti, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2018
Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysisCarmen Criscitiello, Mehra Golshan, William T Barry, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Opportunities and challenges of implementing Pharmacogenomics in cancer drug developmentPaolo Tarantino, Dario Trapani, Stefania Morganti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2019
The evolving landscape of 'next-generation' immune checkpoint inhibitors: A reviewLuca Mazzarella, Bruno Achutti Duso, Dario Trapani, et al.
Critical Reviews in Oncology/Hematology|January 22, 2019
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real lifeStefania Morganti, Paolo Tarantino, Emanuela Ferraro, et al.
Cancer Treatment Reviews|March 5, 2018
Targeting the microenvironment in solid tumorsCarmen Belli, Dario Trapani, Giulia Viale, et al.
Pageof 5